Schabel Fm
Impact in
- Oncology top 2%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis
- Hematology top 5%
- Acute Myeloid Leukemia Research
Papers in
-
- Cancer therapeutics and mechanisms 8
- Biochemical and Molecular Research 5
- Oncology 14
- Cancer Treatment and Pharmacology 5
- Cancer Cells and Metastasis 3
- Co-authors
- Skipper He (27 shared papers)Laster Wr (24 shared papers)Griswold Dp (12 shared papers)Trader Mw (15 shared papers)Corbett Th (8 shared papers)Wilcox Ws (8 shared papers)Montgomery Ja (3 shared papers)Brockman Rw (5 shared papers)
- Journals
- PubMed (60 papers)
- Partner nations
- United States
In The Last Decade
Schabel Fm
59 papers receiving 1.7k citations
Schabel Fm's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 892
- Hematology 216
- Modeling and Simulation 81
- Cancer Research 237
- Genetics 134
Countries citing papers authored by Schabel Fm
This map shows the geographic impact of Schabel Fm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Schabel Fm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Schabel Fm more than expected).
Fields of papers citing papers by Schabel Fm
This network shows the impact of papers produced by Schabel Fm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Schabel Fm. The network helps show where Schabel Fm may publish in the future.
Co-authors
The 15 scholars most cited alongside Schabel Fm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Hit paper breakdown → | 1980 | 357 |
| 2 | Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. | 1963 | 256 |
| 3 | Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. | 1970 | 216 |
| 4 | Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. | 1967 | 178 |
| 5 | Establishment of cross-resistance profiles for new agents. | 1983 | 92 |
| 6 | Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. | 1978 | 82 |
| 7 | Structure-activity relationships observed on screening a series of pyrazolopyrimidines against experimental neoplasms. | 1957 | 60 |
| 8 | Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. | 1978 | 54 |
| 9 | EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA. | 1965 | 53 |
| 10 | Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. | 1984 | 49 |
| 11 | Concepts for controlling drug-resistant tumor cells. | 1980 | 43 |
| 12 | Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. | 1969 | 41 |
| 13 | Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. | 1982 | 37 |
| 14 | Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo. | 1965 | 35 |
| 15 | Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. | 1965 | 35 |
| 16 | Toxicity studies in mice treated with 1-beta-D-arabinofuranosylcytosine (ara-C). | 1969 | 31 |
| 17 | Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. | 1968 | 27 |
| 18 | Spontaneous AK leukemia (lymphoma) as a model system. | 1969 | 26 |
| 19 | Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia. | 1969 | 24 |
| 20 | Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971. | 1972 | 23 |
About Schabel Fm
Schabel Fm is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Public Health, Environmental and Occupational Health and Radiology, Nuclear Medicine and Imaging, having authored 60 papers that have together received 2.1k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (8 papers), Cancer therapeutics and mechanisms (8 papers), Biochemical and Molecular Research (5 papers), Cancer Treatment and Pharmacology (5 papers), Synthesis and biological activity (5 papers), Chronic Lymphocytic Leukemia Research (5 papers), Cancer Cells and Metastasis (3 papers) and Nanoparticle-Based Drug Delivery (3 papers). The work is most often cited by research in Oncology (892 citations), Hematology (216 citations), Modeling and Simulation (81 citations), Cancer Research (237 citations) and Genetics (134 citations). Schabel Fm has collaborated with scholars based in United States. Frequent co-authors include Skipper He, Laster Wr, Griswold Dp, Trader Mw, Corbett Th, Wilcox Ws, Montgomery Ja, Brockman Rw, Mellett Lb and Linda Simpson‐Herren. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.